Helicobacter pylori vaccine - GlaxoSmithKline

Drug Profile

Helicobacter pylori vaccine - GlaxoSmithKline

Latest Information Update: 17 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis; University of Siena
  • Developer GlaxoSmithKline; University of Siena
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Helicobacter infections

Most Recent Events

  • 13 May 2010 Novartis completes a phase I trial in Helicobacter infections in Germany
  • 24 Jul 2008 Phase I development is ongoing
  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top